Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new Long-Acting injection replace opioids after knee surgery?

NCT ID NCT07775248

Symptom relief Sponsor: Henry Ford Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study compares three pain control methods for total knee replacement: a standard injection of pain medicine into the knee during surgery, a new long-acting medication called Zynrelef, and a nerve block given before surgery. The goal is to see if Zynrelef can control pain as well as or better than the other methods, potentially reducing the need for opioid painkillers. Adults undergoing knee replacement will be randomly assigned to one of the three groups and will track their pain and medication use for several weeks after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Zynrelef (extended-release bupivacaine) injected into the knee during surgery, compared with a standard periarticular injection (ropivacaine, epinephrine, ketorolac) and an adductor canal nerve block.
What this could lead to
If Zynrelef works well, it could offer a longer-lasting, opioid-sparing pain relief option for knee replacement patients, potentially improving recovery and reducing opioid use.
What could go wrong
This is a single-center trial, and results may not apply to all patients. Zynrelef may not be superior to existing methods, and there are risks like temporary numbness, weakness, or soreness from injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients age 18 and older undergoing primary total knee replacement by fellowship trained Orthopedic Surgeons in Henry Ford Health System with planned outpatient same-day discharge. Exclusion Criteria: * Incomplete data in medical records * Non-English speakers * Chronic opioid use in the last 3 months * Ipsilateral joint surgery in the last year * Undergoing bilateral knee arthroplasty * Cannot tolerate oral medications * Swallowing difficulties * Intolerance to acetaminophen, anti-inflammatories, muscle relaxants, gabapentinoids, or opioids/tramadol * History of alcohol abuse * Drug abuse * Renal impairment * Peptic ulcer disease * GI bleeding * Illicit narcotic usage in the past 6 months * Chronic liver disease * Chronic pain syndromes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis (OA) of the knee are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis (OA) of the knee

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Henry Ford Medical Center - Grosse Pointe Cottage

    RECRUITING

    Grosse Pointe Farms, Michigan, 48236, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.